Disagree on all accounts. Biotech stocks are not valued like other companies. If MSB successful end point P3 CHF drug approved, first of its kind stem cell treatment in the world.
The stock will explode. At $4 thats a tiny valuation.
Companies are being purchased in the USA in biotech that have one drug for one indication for multiple billions.
Why? Because its not like a product that can be imitated. Its a global patent that says you get to print money for X number of years.
Bockbuster or potential blockbuster drugs which CHF might be are worth in the billions annually globally.
What you're talking about with a steady climb to $4 and maybe $10 within a decade sounds like you're referring to Oil and Gas play rather than a biotech.
If we get drugs approved to market or CHF p3 good read outs. The company is worth multiple billions overnight. Did you not recall that MSB hit $11 dollars or so based on the promise alone?
If verified and approved we'd be in the $teens for sure. Couldn't say how long that might take but 10 years is just grossly in error.
MSB Price at posting:
$1.51 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)